Financial Performance - The company's operating revenue for Q1 2025 was ¥295,809,077.01, a decrease of 6.93% compared to ¥317,837,248.06 in the same period last year[3]. - Net profit attributable to shareholders was ¥84,541,584.10, down 10.93% from ¥94,914,703.56 year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 31.10% to ¥74,348,646.47 from ¥56,710,261.61 in the previous year[3]. - The company reported a significant reduction in sales expenses, which were CNY 47,606,390.41 in Q1 2025, down from CNY 55,549,586.13 in Q1 2024, a decrease of 14.5%[18]. - R&D expenses for Q1 2025 amounted to ¥22,593,979, a decrease from ¥25,925,876 in Q1 2024, representing a reduction of approximately 12.5%[19]. - The company reported a total comprehensive income of ¥84,462,553 for Q1 2025, down from ¥94,943,374 in Q1 2024, a decrease of approximately 10.9%[20]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.20, compared to ¥0.22 in Q1 2024, reflecting a decrease of about 9.1%[20]. Cash Flow and Assets - The net cash flow from operating activities decreased by 57.32% to ¥49,858,333.75, compared to ¥116,831,752.91 in the same period last year[3]. - Cash and cash equivalents as of March 31, 2025, were CNY 266,908,551.12, up from CNY 216,438,010.50 as of December 31, 2024[12]. - The cash and cash equivalents at the end of Q1 2025 were ¥266,908,551, down from ¥353,290,368 at the end of Q1 2024, a reduction of approximately 24.4%[25]. - Total current assets increased to CNY 1,365,467,204.82 as of March 31, 2025, compared to CNY 1,315,371,516.39 at the end of 2024, reflecting a growth of 3.8%[13]. - Total assets at the end of the reporting period were ¥1,898,404,039.40, an increase of 2.41% from ¥1,853,685,995.71 at the end of the previous year[4]. - Total assets reached CNY 1,898,404,039.40 as of March 31, 2025, compared to CNY 1,853,685,995.71 at the end of 2024, indicating an increase of 2.4%[15]. - Total liabilities decreased to CNY 428,499,279.10 as of March 31, 2025, down from CNY 468,243,788.84 at the end of 2024, a reduction of 8.5%[14]. - Shareholders' equity increased to CNY 1,469,904,760.30 as of March 31, 2025, compared to CNY 1,385,442,206.87 at the end of 2024, reflecting a growth of 6.1%[15]. Government Support and Non-Recurring Items - The company received government subsidies amounting to ¥10,284,362.89, which are closely related to its normal business operations[5]. - The company reported a significant increase in non-recurring profit attributable to shareholders, totaling ¥10,192,937.63 for the period[5]. - Other income increased significantly to ¥11,024,022 in Q1 2025 from ¥2,059,800 in Q1 2024, representing a growth of approximately 434.5%[19]. Shareholder Information - The company’s major shareholder, Tibet Weixin Kang Enterprise Management Co., Ltd., holds 47.17% of the shares[9]. Operational Insights - The company has not disclosed any new product developments or market expansion strategies in this report[2]. - Total operating costs for Q1 2025 were CNY 218,069,920.73, down 14.8% from CNY 256,009,406.33 in Q1 2024[18]. - Operating costs included CNY 118,788,405.38 in cost of goods sold, a decrease of 17.5% from CNY 143,932,007.71 in Q1 2024[18]. - Investment activities generated a net cash flow of ¥8,351,201 in Q1 2025, contrasting with a negative cash flow of ¥29,630,226 in Q1 2024[24].

Financial Performance - The company's operating revenue for 2024 was CNY 1,300,234,520.39, representing a decrease of 1.69% compared to CNY 1,322,649,286.86 in 2023[22]. - The net profit attributable to shareholders of the listed company reached CNY 246.17 million, a year-on-year increase of 15.02%[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 201.39 million, up 22.86% year-on-year[23]. - Operating cash flow amounted to CNY 372.78 million, representing a 54.61% increase compared to the previous year[23]. - Basic earnings per share increased to CNY 0.57, a 14.00% rise from the previous year[24]. - Total revenue for the year was CNY 1.30 billion, a decrease of 1.69% compared to the previous year[34]. - The total cash dividend distributed for the year, including interim dividends, amounted to CNY 148,316,426.97, which is 60.25% of the net profit attributable to shareholders[6]. - The total amount spent on share repurchases during the year was CNY 29,983,682.50, bringing the combined total of cash dividends and repurchase amounts to CNY 178,300,109.47, or 72.43% of the net profit attributable to shareholders[6]. Dividend Policy - The proposed cash dividend for 2024 is CNY 1.80 per 10 shares, totaling CNY 77,820,264.00 based on the adjusted total share capital of 432,334,800 shares[6]. - The total cash dividend distributed in the last accounting year was 178.3 million CNY, which represents 72.43% of the net profit attributable to ordinary shareholders[185]. - The cumulative cash dividend amount over the last three accounting years was 374.6 million CNY (including tax)[186]. Risk Management - The company has not identified any significant risks that could materially impact its operations during the reporting period[9]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company emphasizes the importance of product quality and adheres to the latest GMP and GSP standards to mitigate quality risks, ensuring product safety and reducing potential impacts on operational performance[148]. - The company is actively managing R&D risks associated with high investment and long cycles, implementing effective risk assessment and control mechanisms to ensure product development remains manageable[149]. Research and Development - The company has over 40 new product projects in development, with 5 expected to receive approval by 2025[42]. - The company emphasizes R&D innovation based on clinical needs, aiming to develop new products with independent intellectual property rights[56]. - The company is focused on expanding its product offerings in the parenteral nutrition market, targeting both adult and pediatric populations[60]. - The company aims to enhance its R&D capabilities and focus on innovative drug development, particularly in perioperative and pediatric medication[137]. Product Development and Market Access - The company has completed access to 31 provincial-level administrative regions for its injectable multivitamins product[34]. - The pediatric multivitamin injection achieved sales revenue of CNY 69.70 million in 2024, representing a year-on-year growth of 53.16%[36]. - The company has completed market access for the pediatric compound amino acid injection in 30 provincial administrative regions by the end of the reporting period[36]. - The company has obtained drug registration certificates for four products, including aspartate potassium injection and multiple trace element injection (I)[41]. - The company has completed market access for the inhaled acetylcysteine solution in 27 provincial administrative regions by the end of the reporting period[37]. Corporate Governance - The company has established a governance structure that includes a board of directors with 7 members, including 3 independent directors with expertise in accounting, law, and pharmaceuticals, ensuring compliance with legal requirements[152]. - The company has a performance evaluation and incentive mechanism in place, assessing senior management and employees annually based on company performance and individual contributions, fostering a fair and efficient work environment[153]. - The company has conducted its annual shareholder meeting, approving all 15 proposals, including the annual financial report and profit distribution plan, ensuring transparency and shareholder engagement[155]. Environmental Responsibility - The company invested 2.2885 million yuan in environmental protection during the reporting period[194]. - The company’s wastewater treatment capacity is 200 m³ per day, with a treatment process that meets the B-level standards of the urban sewage discharge quality[197]. - The company has achieved a 100% compliance rate for solid waste disposal, with no incidents of environmental pollution or occupational accidents reported[198]. - The company ensures compliance with labor laws and occupational health regulations to create a healthy and safe working environment for employees[200].

关于使用自有资金进行证券投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603676 证券简称：卫信康 公告编号：2025-020 西藏卫信康医药股份有限公司 一、投资情况概述 （一）证券投资目的 在保证公司正常经营所需流动资金和有效控制风险的前提下，为提高资金使 用效率，降低财务成本，创造更大的经济效益，公司及全资子公司拟使用暂时闲 置的自有资金进行证券投资。 （二）证券投资金额 投资种类：证券投资，包括新股配售或者申购、证券回购、股票及存托 凭证投资、债券投资以及上海证券交易所认定的其他投资行为。 投资金额：最高额度人民币 1 亿元，资金可滚动使用。 已履行及拟履行的审议程序：西藏卫信康医药股份有限公司（以下简称 "公司"）于 2025 年 4 月 25 日召开第三届董事会第十四次会议、第三届监事会 第十三次会议，审议通过了《关于使用自有资金进行证券投资的议案》。本议案 无需提交公司股东大会审议。 特别风险提示：金融市场受宏观经济、投资标的选择、市场环境等因素 影响，公司进行证券投资业 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-017 西藏卫信康医药股份有限公司 2024 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一） 实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准西藏卫信康医药股份有限公司首次公开发行股票的 批复》（证监许可〔2017〕1098 号）核准，西藏卫信康医药股份有限公司（以下简称"公司"） 公开发行人民币普通股（A 股）6,300 万股，每股面值人民币 1 元，每股发行价格为人民币 5.53 元，募集资金为人民币 348,390,000.00 元，扣除与发行有关的费用（不含税）人民币 51,354,558.49 元后，募集资金净额为 297,035,441.51 元，款项已由主承销商中信证券股份 有限公司（以下简称"中信证券"）于 2017 年 7 月 17 日汇入公司募集资金监管账户。上述募 集资金到位情况经瑞华会计师事务所（特殊普通合伙）验证，并由其出具瑞华验字第 [2017]01 ...

西藏卫信康医药股份有限公司 2024 年度 募集资金年度存放与使用情况鉴证报告 | 索引 | 页码 | | --- | --- | | 鉴证报告 | 1-2 | | 关于募集资金 2024 年度存放与使用情况的专项报告 | 1-11 | 联系申话· 北京市东城区朝阳门北大街 出水研医疗分分级母系统 telenhone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 9/F. Block A. Fu Hua I No.8. Chaovangmen Be ShineWin certified public accountants 100027. P.R.China 我们按照《中国注册会计师其他鉴证业务准则第 3101 号-历史财务信息审计或审阅 以外的鉴证业务》的规定执行了鉴证工作,以对募集资金年度存放与使用情况专项报告 是否不存在重大错报获取合理保证。在执行鉴证工作的过程中,我们实施了询问、检查、 重新计算等我们认为必要的鉴证程序,选择的程序取决于我们的职业判断。我们相信, 我们的鉴证工作为发表意见提供了合理的基础。我们认为,卫信康上述募集资金年度存 放与使用情况专项报告已经按照上海证 ...

中信证券股份有限公司关于西藏卫信康医药股份有限公司 2024年度募集资金年度存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为西藏 卫信康医药股份有限公司（以下简称"卫信康"或"公司"）首次公开发行股票 并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 股票上市规则》《上市公司监管指引第2号——上市公司募集资金管理和使用的 监管要求》和《上海证券交易所上市公司自律监管指引第1号——规范运作》等 有关规定，就卫信康2024年度募集资金的存放与使用情况进行了核查，具体情况 如下： 一、募集资金基本情况 （一）实际募集资金金额 经中国证券监督管理委员会《关于核准西藏卫信康医药股份有限公司首次公 开发行股票的批复》（证监许可〔2017〕1098 号）核准，西藏卫信康医药股份有 限公司（以下简称"公司"）公开发行人民币普通股（A 股）6,300 万股，每股面 值人民币 1 元，每股发行价格为人民币 5.53 元，募集资金为人民币 348,390,000.00 元，扣除与发行有关的费用（不含税）人民币 51,354,558.49 元后，募集资金净额 为 29 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-021 西藏卫信康医药股份有限公司 关于申请 2025 年度综合授信额度及相关担保事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人：西藏卫信康医药股份有限公司（以下简称"公司"）及合并报 表范围内的子公司。 本次预计担保额度及已实际为其提供的担保余额：公司及子公司 2025 年拟向包括但不限于中国工商银行股份有限公司拉萨分行等在内的金融机构申 请不超过人民币 15 亿元的综合授信及用信额度，并由公司及子公司就前述授信 及用信额度提供担保。截至本公告披露日，公司及子公司实际对外担保余额为 0 元。 一、本次申请综合授信额度及相关担保事项概述 | 公司名称 | 西藏中卫诚康药业有限公司 | | --- | --- | | 统一社会信用代码 | 9154009109577063X8 | | 注册地址 | 拉萨经济技术开发区 区园区南路 号工业中心 号 B 5 4 | | | 楼 3 层 | | 注册资本 | 17,500 万元 | | ...

证券代码：603676 证券简称：卫信康 公告编号：2025-019 西藏卫信康医药股份有限公司 关于使用自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 理财金额：最高额度人民币 12 亿元（含等值外币，以下同），资金可滚 动使用。 已履行及拟履行的审议程序：西藏卫信康医药股份有限公司（以下简称 "公司"）于 2025 年 4 月 25 日召开第三届董事会第十四次会议、第三届监事会 第十三次会议，审议通过了《关于使用自有资金购买理财产品的议案》。本议案 尚需提交公司 2024 年年度股东大会审议。 特别风险提示：1、尽管公司购买的理财产品属于流动性好、风险等级为 R2、稳健型、中低风险、二级及以下风险等级的理财产品，但金融市场受宏观经 济的影响较大，公司购买的理财产品可能面对市场风险、流动性风险、信用风险、 管理风险等投资风险，从而可能对公司理财资金和预期收益产生影响。2、公司 及全资子公司将根据经济形势以及金融市场的变化适时适量的介入，因此投资的 实际收益不可预期。3、相关工作人员的操作风险。 一 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-022 西藏卫信康医药股份有限公司 关于确认 2024 年度日常关联交易执行情况及预计 2025 年度 日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次日常关联交易事项为董事会决策权限，无须提交股东大会审议。 日常关联交易对公司的影响：西藏卫信康医药股份有限公司（以下简称 "公司"）的日常关联交易是根据公司生产经营需要而发生，有利于经营业务的 延续及资源的优化配置。公司与关联方发生的日常关联交易均遵循了公开、公平、 公正的定价原则，不会对公司未来的财务状况、经营成果产生不利影响，不会对 关联方形成依赖，也不会影响公司的独立性。 一、日常关联交易基本情况 本议案在提交公司董事会审议之前，已经公司第三届董事会独立董事专门会 议第二次会议审议并获全票同意。 2、2024 年度日常关联交易的预计和执行情况 单位：人民币万元 | 类别 | | | | 方式 | 异较大的原因 | | --- | --- | --- | --- | --- ...

西藏卫信康医药股份有限公司 董事会审计委员会 2024 年度履职情况报告 各位董事： 根据《公司章程》《董事会专门委员会工作制度》等有关规定，2024 年度， 西藏卫信康医药股份有限公司（以下简称"公司"）董事会审计委员会勤勉尽责、 恪尽职守，切实有效地监督公司的外部审计，指导公司内部审计工作，促进公司 建立有效的内部控制。现将董事会审计委员会 2024 年度履职情况报告如下： 一、审计委员会组成情况 公司第三届董事会审计委员会由 3 位成员组成，并由会计专业人士许晓芳女 士担任主任委员。 根据《国务院办公厅关于上市公司独立董事制度改革的意见》，上市公司董 事会应当设立审计委员会，成员全部由非执行董事组成，其中独立董事占多数。 为完善公司治理结构，报告期内，公司对第三届董事会审计委员会委员进行调整： 公司董事刘彬彬女士不再担任审计委员会委员，董事会选举独立董事曹磊女 士担任审计委员会委员，任期自董事会审议通过之日起至第三届董事会届满之日 止，其余委员保持不变。本次调整后，公司审计委员会委员全部由独立董事担任。 调整前后的审计委员会委员情况如下： 调整前：许晓芳女士（主任委员）、赵艳萍女士、刘彬彬女士 （一） ...